Sanofi-aventis Delivers 2008 Results Above Guidance
...iven by the adjuvant indication. In the "Other Countries" region, the product reported robust growth of 13.4% to EUR 186 million.
Net sales of acomplia
(R) , which was withdrawn from the market in the fourth quarter, totaled EUR 72 million in 2008.
Worldwide presence(1) of Plavix (R) / Is...
Obesity Drug Shows Mixed Success Against Atherosclerosis
... Hope is that acomplia
might help fight coronary disease
TUES..., April 1 (HealthDay News) -- The weight-loss drug acomplia
may or may not help slow atherosclerosis, a buildu...in one measure of plaque build-up in arteries.
also showed a high rate of psychiatric side effect...
Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016
...nditions such as obesity poses one of the most significant
threats to companies developing anti-obesity drugs. For example, although
Sanofi- Aventis's acomplia
(rimonabant) had been widely anticipated to
become a key therapy for obesity, its blockbuster potential was eliminated
after a negative opinion of the...
Pain receptor in brain may be linked to learning and memory
...e other implication may be cautionary. Drug makers already sell drugs such as the weight-loss pill rimonabant, which is sold in Europe under the name acomplia
that can block TRPV1 receptors. Other drugs aimed at reducing pain and inflammation by blocking or activating TRPV1 receptors are in the research pip...
Possible Reason for Rimonabant's Side Effects Discovered
...1 at all," Kauer said. "However, in some patients, acomplia
could be hitting TRPV1 and may well have an effect on activating this receptor," she said.
is used widely outside the United States. To date,...U.S. Food and Drug Administration has not approved acomplia
because of its psychiatric side effects.
Pipeline for New Obesity Therapies is Focus of New Report
...anisms, including follow up approaches after orlistat, and novel approaches such as SGLT inhibition.
Key drugs discussed in this report include: acomplia
Sanofi-Aventis), taranabant (MK-0364; Merck), CP-945598 (Pfizer), SLV 319
(BMS-646256; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-16...
EU Drug Regulator Highlights Depression Danger of Weight-loss Pill
... The European drug regulator EMEA said Thursday it had maintained authorisation of weight-loss pill acomplia
in the European Union, but had ordered it to be withheld from people suffering from depression.
A panel of experts from the US Food and Drug ...
UK Reports Psychiatric Reactions to Weight-loss Drug Rimonabant
... said evidence suggested one in 10 people who take acomplia
may develop psychiatric side effects.
"Approx...monabant since it was launched there in June 2006. acomplia
is manufactured by Sanofi-aventis, worlds fourth l...carry a warning "that doctors should not prescribe acomplia
in patients with uncontrolled serious psychiatric ...
Sanofi Withdraws Anti-obesity Drug in US
... French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug acomplia
in the United States.
A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, re...
Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
...tself, reports an article in the June issue of Drug and Therapeutics Bulletin (DTB).
Advertisements for rimonabant (sold under the brand name acomplia
by Sanofi-Aventis) claim that an estimated 50% of the effects on cardiometabolic risk factors are beyond those expected from weight loss alone. But D...